Literature DB >> 24176426

Clinical neurogenetics: friedreich ataxia.

Abigail Collins1.   

Abstract

Friedreich ataxia is the most common autosomal recessive ataxia. It is a progressive neurodegenerative disorder, typically with onset before 20 years of age. Signs and symptoms include progressive ataxia, ascending weakness and ascending loss of vibration and joint position senses, pes cavus, scoliosis, cardiomyopathy, and arrhythmias. There are no disease-modifying medications to either slow or halt the progression of the disease, but research investigating therapies to increase endogenous frataxin production and decrease the downstream consequences of disrupted iron homeostasis is ongoing. Clinical trials of promising medications are underway, and the treatment era of Friedreich ataxia is beginning.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autosomal recessive; Friedreich ataxia; Mitochondria; Neurodegenerative disease; Triplet repeat expansion

Mesh:

Substances:

Year:  2013        PMID: 24176426     DOI: 10.1016/j.ncl.2013.05.002

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  6 in total

1.  Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia.

Authors:  Antonio Costantini; Tiziana Laureti; Maria Immacolata Pala; Marco Colangeli; Simona Cavalieri; Elisa Pozzi; Alfredo Brusco; Sandro Salvarani; Carlo Serrati; Roberto Fancellu
Journal:  J Neurol       Date:  2016-08-03       Impact factor: 4.849

2.  Friedreich Ataxia in Classical Galactosaemia.

Authors:  Siobhán Neville; Siobhan O'Sullivan; Bronagh Sweeney; Bryan Lynch; Donncha Hanrahan; Ina Knerr; Sally Ann Lynch; Ellen Crushell
Journal:  JIMD Rep       Date:  2015-07-29

3.  Identification of p38 MAPK as a novel therapeutic target for Friedreich's ataxia.

Authors:  M Grazia Cotticelli; Shujuan Xia; Avinash Kaur; Daniel Lin; Yongping Wang; Eric Ruff; John W Tobias; Robert B Wilson
Journal:  Sci Rep       Date:  2018-03-22       Impact factor: 4.379

Review 4.  Clinical and genetic aspects of defects in the mitochondrial iron-sulfur cluster synthesis pathway.

Authors:  A V Vanlander; R Van Coster
Journal:  J Biol Inorg Chem       Date:  2018-04-05       Impact factor: 3.358

5.  Activating frataxin expression by repeat-targeted nucleic acids.

Authors:  Liande Li; Masayuki Matsui; David R Corey
Journal:  Nat Commun       Date:  2016-02-04       Impact factor: 14.919

6.  E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia.

Authors:  Monica Benini; Silvia Fortuni; Ivano Condò; Giulia Alfedi; Florence Malisan; Nicola Toschi; Dario Serio; Damiano Sergio Massaro; Gaetano Arcuri; Roberto Testi; Alessandra Rufini
Journal:  Cell Rep       Date:  2017-02-21       Impact factor: 9.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.